返回
BioMarin Pharmaceutical Inc（BMRN）價格
BMRN 股價走勢圖
BMRN 收益
BioMarin Pharmaceutical Inc
$54.59
-0.87%
$-0.47
收盤價：Jan 16, 16:00:00 GMT-5
$54.9
0.56%
$0.3
盤後：Jan 16, 20:00:00 GMT-5
B+
最終分數
關鍵數據
前收市價
$55.07
開盤價
$55
當日範圍
$54.58 - $55.21
52週區間
$50.76 - $73.51
交易量
2.0M
平均成交量
2.9M
每股盈餘 (TTM)
2.64
股息收益率
--
市值
$10.5B
什麼是 BMRN？
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in San Rafael California, California and currently employs 3,040 full-time employees. The firm has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.